Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)	BioMarin Pharmaceutical Inc.	Completed	BMN 110	3	MOR-004	KFSH & RC-R
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2)	Sponsor (Global Blood Therapeutics, Inc.)	Ongoing	Voxelotor (GBT440)	3	GBT440-032	King Khalid University Hospital (Riyadh)
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes	Intarcia Therapeutics	Completed	ITCA 650	3	ITCA 650-CLP-105	NGHA-J
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23 Valent pneumococcal polysacchride Vaccine.	Pfizer(Wyeth)	Completed	13-valent Pneumoccocal Conjugate Vaccine	3	B1851013	KFSH & RC-R
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis” LUCENT 2	Eli Lilly	Ongoing	Mirikizumab	3	I6T-MC-AMBG	KFSH-D
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 1	Eli Lilly	Ongoing	Mirikizumab	3	I6T-MC-AMAN	KFSH-D
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease	Celgene	Ongoing	Ozanimod HCl	3	RPC01-3203	KAUH-J
A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	Novartis	Ongoing	ABL001 (asciminib)	3	CABL001A2301	KFSH&RC-R
"A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3"	Eli Lilly	Completed	Mirikizumab	3	I6T-MC-AMAP	King Fahad Specialist Hospital (Dammam)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease	Celgene	Ongoing	Ozanimod HCl	3	RPC01-3204	KAUH-J